Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$200.62M

FY 2025 · Annual

Investing Cash Flow

$116.77M

FY 2025 · Annual

Financing Cash Flow

$28.06M

FY 2025 · Annual

-69.3% YoY

Cash Flow Statement

USD

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$223.0M
+ D&A$13.2M
+ Stock-Based Comp$20.6M
+ Deferred Tax$0
- Working Capital-$14.6M
+ Other Non-Cash$3.2M
= Operating Cash Flow-$200.6M
- Capex-$3.5M
= Free Cash Flow-$204.1M

Analysis

FY2025 free cash flow is -$204.1M. FCF conversion is 91.6% of net income. Operating cash flow was -$200.6M, with capex of -$3.5M. The largest bridge item is Stock-Based Comp at $20.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
SC 13GSC 13G filingNov 5, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipSep 3, 2026

Does GENB generate free cash flow?

Generate Biomedicines, Inc. (GENB) generated -$204.13M of free cash flow in fiscal 2025.

How much operating cash flow does GENB produce?

Operating cash flow was -$200.62M, before capital expenditures of $3.51M.